Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
Ellen Q WangJack F BukowskiCarla YunisCharles L ShearPaul M RidkerPamela F SchwartzDaniel BaltrukonisPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2020)
The SPIRE-HR study is registered on ClinicalTrials.gov under the identifier NCT01968954.
Keyphrases